Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Haptogen

2002 FOUNDED
M&A STATUS
11-20 EMPLOYEES
M&A LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Provider of drug development services intended for discovery and optimization of protein therapeutics. The company's drug development services involves engineering antibodies to develop more tailored and less toxic treatment for key diseases such as cancer.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Acquirer
Primary Office
  • Polwarth Building
  • Foresterhill
  • Aberdeen AB25 2ZD
  • Scotland

Haptogen Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Haptogen‘s full profile, request access.

Request full access to PitchBook

Haptogen Executive Team (2)

Name Title Board
Seat
Contact
Info
Jim Reid Co-Founder & Chief Executive Officer
Andrew Porter Ph.D Co-Founder & Chief Scientific Officer